These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 33023630

  • 1. Functional benefits of corticosteroid and IVIG combination therapy in a coronary artery endothelial cell model of Kawasaki disease.
    Inoue T, Murakami S, Matsumoto K, Matsuda A.
    Pediatr Rheumatol Online J; 2020 Oct 06; 18(1):76. PubMed ID: 33023630
    [Abstract] [Full Text] [Related]

  • 2. Monocyte-Derived Interleukin-1β As the Driver of S100A12-Induced Sterile Inflammatory Activation of Human Coronary Artery Endothelial Cells: Implications for the Pathogenesis of Kawasaki Disease.
    Armaroli G, Verweyen E, Pretzer C, Kessel K, Hirono K, Ichida F, Okabe M, Cabral DA, Foell D, Brown KL, Kessel C.
    Arthritis Rheumatol; 2019 May 06; 71(5):792-804. PubMed ID: 30447136
    [Abstract] [Full Text] [Related]

  • 3. Anti-inflammatory effects of high-dose IgG on TNF-α-activated human coronary artery endothelial cells.
    Matsuda A, Morita H, Unno H, Saito H, Matsumoto K, Hirao Y, Munechika K, Abe J.
    Eur J Immunol; 2012 Aug 06; 42(8):2121-31. PubMed ID: 22585560
    [Abstract] [Full Text] [Related]

  • 4. Anti-inflammatory effect of intravenous immunoglobulin in comparison with dexamethasone in vitro: implication for treatment of Kawasaki disease.
    Makata H, Ichiyama T, Uchi R, Takekawa T, Matsubara T, Furukawa S.
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Aug 06; 373(5):325-32. PubMed ID: 16896803
    [Abstract] [Full Text] [Related]

  • 5. Prednisolone Suppresses the Extracellular Release of HMGB-1 and Associated Inflammatory Pathways in Kawasaki Disease.
    Ueno K, Nomura Y, Morita Y, Kawano Y.
    Front Immunol; 2021 Aug 06; 12():640315. PubMed ID: 34079539
    [Abstract] [Full Text] [Related]

  • 6. [Recombinant human interleukin 35 (rhIL-35) alleviates the damage of coronary artery endothelial cells in Kawasaki disease by inhibiting NF-κB pathway].
    Tian Z, Zhou Z, Yang Y, Li J, Hu L, Jiao R.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Oct 06; 38(10):880-885. PubMed ID: 36163618
    [Abstract] [Full Text] [Related]

  • 7. Anti-inflammatory effect of resveratrol in human coronary arterial endothelial cells via induction of autophagy: implication for the treatment of Kawasaki disease.
    Huang FC, Kuo HC, Huang YH, Yu HR, Li SC, Kuo HC.
    BMC Pharmacol Toxicol; 2017 Jan 09; 18(1):3. PubMed ID: 28069066
    [Abstract] [Full Text] [Related]

  • 8. [Biomarkers associated with unresponsiveness to IVIG in children with Kawasaki disease].
    Abe J, Matsuda A.
    Nihon Rinsho Meneki Gakkai Kaishi; 2013 Jan 09; 36(1):27-34. PubMed ID: 23445729
    [Abstract] [Full Text] [Related]

  • 9. The effects of glucocorticoid plus intravenous immunoglobulin (IVIG) vs IVIG alone on platelet activation in children with Kawasaki disease.
    Wang QQ, Zheng LY, Zhao S.
    Turk J Pediatr; 2023 Jan 09; 65(4):640-649. PubMed ID: 37661679
    [Abstract] [Full Text] [Related]

  • 10. HMGB1 gene polymorphism is associated with coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease.
    Ahn JG, Bae Y, Shin D, Nam J, Kim KY, Kim DS.
    Rheumatology (Oxford); 2019 May 01; 58(5):770-775. PubMed ID: 30535242
    [Abstract] [Full Text] [Related]

  • 11. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
    Lim YJ, Jung JW.
    Yonsei Med J; 2014 Sep 01; 55(5):1260-6. PubMed ID: 25048483
    [Abstract] [Full Text] [Related]

  • 12. 1α,25-Dihydroxyvitamin D(3) inhibits vascular cellular adhesion molecule-1 expression and interleukin-8 production in human coronary arterial endothelial cells.
    Kudo K, Hasegawa S, Suzuki Y, Hirano R, Wakiguchi H, Kittaka S, Ichiyama T.
    J Steroid Biochem Mol Biol; 2012 Nov 01; 132(3-5):290-4. PubMed ID: 22841897
    [Abstract] [Full Text] [Related]

  • 13. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm.
    Wu Y, Liu FF, Xu Y, Wang JJ, Samadli S, Wu YF, Liu HH, Chen WX, Luo HH, Zhang DD, Wei W, Hu P.
    Clin Exp Med; 2019 May 01; 19(2):173-181. PubMed ID: 30617865
    [Abstract] [Full Text] [Related]

  • 14. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.
    Chen S, Dong Y, Yin Y, Krucoff MW.
    Heart; 2013 Jan 01; 99(2):76-82. PubMed ID: 22869678
    [Abstract] [Full Text] [Related]

  • 15. IL-1 Signaling Is Critically Required in Stromal Cells in Kawasaki Disease Vasculitis Mouse Model: Role of Both IL-1α and IL-1β.
    Lee Y, Wakita D, Dagvadorj J, Shimada K, Chen S, Huang G, Lehman TJ, Fishbein MC, Hoffman HM, Crother TR, Arditi M.
    Arterioscler Thromb Vasc Biol; 2015 Dec 01; 35(12):2605-16. PubMed ID: 26515418
    [Abstract] [Full Text] [Related]

  • 16. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
    Postgrad Med; 2018 May 01; 130(4):442-447. PubMed ID: 29745742
    [Abstract] [Full Text] [Related]

  • 17. Berberine protects Kawasaki disease-induced human coronary artery endothelial cells dysfunction by inhibiting of oxidative and endoplasmic reticulum stress.
    Xu M, Qi Q, Men L, Wang S, Li M, Xiao M, Chen X, Wang S, Wang G, Jia H, Liu C.
    Vascul Pharmacol; 2020 Apr 01; 127():106660. PubMed ID: 32070767
    [Abstract] [Full Text] [Related]

  • 18. Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.
    Ge X, Li CR, Yang J, Wang GB.
    Scand J Immunol; 2013 May 01; 77(5):389-97. PubMed ID: 23298273
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
    Lancet Child Adolesc Health; 2018 Dec 01; 2(12):855-862. PubMed ID: 30337183
    [Abstract] [Full Text] [Related]

  • 20. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).
    Tremoulet AH, Jain S, Kim S, Newburger J, Arditi M, Franco A, Best B, Burns JC.
    Contemp Clin Trials; 2016 May 01; 48():70-5. PubMed ID: 27080929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.